echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The 4th domestically produced! Chia Tai Tianqing will take antipsychotic drugs that skyrocketed 30 times

    The 4th domestically produced! Chia Tai Tianqing will take antipsychotic drugs that skyrocketed 30 times

    • Last Update: 2021-12-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product
    .
    According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
    .

     
     
    Data show that Lurasidone is an atypical (second-generation) antipsychotic drug developed by Sumitomo Pharmaceuticals
    .
    The product was approved by the U.
    S.
    FDA in 2010 and approved for listing in China in 2019.
    In 2020, its global sales reached 194.
    2 billion yen (approximately 1.
    7 billion U.
    S.
    dollars)
    .

     
    Sales of Lurasidone Hydrochloride Tablets in Chinese Urban Entity Pharmacies in Recent Years
    Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      According to data from Meinnet.
    com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
    .
     
      Top 10 terminal antipsychotic products in physical pharmacies in Chinese cities
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      It is worth mentioning that Lurasidone Hydrochloride Tablets, with its strong growth rate, jumped to the 12th place in the TOP20 antipsychotic products in 2020, and is expected to rise to the 10th place in 2021, with amazing potential
    .
     
      At present, Lurasidone Hydrochloride Tablets has 4 manufacturers including the original research
    .
    In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
    The same comment
    .
    A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
    .
    In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
    .
     
      Data source: official website of the State Food and Drug Administration, Mynet database
     
      Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .

      Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product
    .
    According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
    .

     
     
      Data show that Lurasidone is an atypical (second-generation) antipsychotic drug developed by Sumitomo Pharmaceuticals
    .
    The product was approved by the U.
    S.
    FDA in 2010 and approved for listing in China in 2019.
    In 2020, its global sales reached 194.
    2 billion yen (approximately 1.
    7 billion U.
    S.
    dollars)
    .

     
      Sales of Lurasidone Hydrochloride Tablets in Chinese Urban Entity Pharmacies in Recent Years
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      According to data from Meinnet.
    com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
    .
     
      Top 10 terminal antipsychotic products in physical pharmacies in Chinese cities
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      It is worth mentioning that Lurasidone Hydrochloride Tablets, with its strong growth rate, jumped to the 12th place in the TOP20 antipsychotic products in 2020, and is expected to rise to the 10th place in 2021, with amazing potential
    .
     
      At present, Lurasidone Hydrochloride Tablets has 4 manufacturers including the original research
    .
    In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
    The same comment
    .
    A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
    .
    In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
    .
     
      Data source: official website of the State Food and Drug Administration, Mynet database
     
      Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .

      Recently, the official website of the State Food and Drug Administration showed that Chia Tai Tianqing Pharmaceutical entered the administrative examination and approval stage with the imitation of lurasidone hydrochloride tablets reported for production in category 4, and it is expected to become the fourth domestic company approved for this product
    .
    According to data from Meinenet, the sales growth rate of lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 is astonishing, exceeding 30 times; sales are expected to reach a new high in 2021
    .

     
     
      Data show that Lurasidone is an atypical (second-generation) antipsychotic drug developed by Sumitomo Pharmaceuticals
    .
    The product was approved by the U.
    S.
    FDA in 2010 and approved for listing in China in 2019.
    In 2020, its global sales reached 194.
    2 billion yen (approximately 1.
    7 billion U.
    S.
    dollars)
    .

     
      Sales of Lurasidone Hydrochloride Tablets in Chinese Urban Entity Pharmacies in Recent Years
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      According to data from Meinnet.
    com, although the sales of terminal lurasidone hydrochloride tablets in physical pharmacies in Chinese cities in 2020 are less than 10 million yuan, the growth rate is rapid, with a year-on-year increase of more than 30 times; sales are expected to reach a new high in 2021
    .
     
      Top 10 terminal antipsychotic products in physical pharmacies in Chinese cities
      Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern
     
      It is worth mentioning that Lurasidone Hydrochloride Tablets, with its strong growth rate, jumped to the 12th place in the TOP20 antipsychotic products in 2020, and is expected to rise to the 10th place in 2021, with amazing potential
    .
     
      At present, Lurasidone Hydrochloride Tablets has 4 manufacturers including the original research
    .
    In April of this year, Zhejiang Hisun Pharmaceutical won the first imitation; in June, Jiangsu Haosen Pharmaceutical and Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical were approved successively, and all three domestic companies were approved for imitation 4 types of production.
    The same comment
    .
    A few days ago, Chia Tai Tianqing Pharmaceutical entered the stage of administrative approval and is expected to become the fourth domestic company approved for this product
    .
    In addition, Lurasidone Hydrochloride Tablets and Zhejiang Huahai Pharmaceutical and other three companies submitted their listing applications for review and approval
    .
    Enterprise business enterprise
     
      Data source: official website of the State Food and Drug Administration, Mynet database
      Data source: official website of the State Food and Drug Administration, Mynet database
     
      Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .
    The above sales are calculated based on the average retail price of the product at the terminal
    .

    Pharmacy pharmacy pharmacy
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.